A phase II, 28-day, randomized, parallel-group, open-label study evaluating the efficacy and safety of twice daily oral doses of testosterone (150-400mg) co-administered with 0.25mg dutasteride compared with 400mg testosterone alone and 0.25mg dutasteride alone in the treatment of hypogonadism.

Trial Profile

A phase II, 28-day, randomized, parallel-group, open-label study evaluating the efficacy and safety of twice daily oral doses of testosterone (150-400mg) co-administered with 0.25mg dutasteride compared with 400mg testosterone alone and 0.25mg dutasteride alone in the treatment of hypogonadism.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Jun 2017

At a glance

  • Drugs Dutasteride (Primary) ; Testosterone (Primary)
  • Indications Hypogonadism
  • Focus Adverse reactions; Biomarker; Pharmacokinetics
  • Most Recent Events

    • 13 Jun 2009 Results presented at the 91st Annual Meeting of the Endocrine Society
    • 12 Oct 2008 Status changed from discontinued to completed.
    • 30 Jan 2008 Status changed from in progress to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top